|
Age group (years)a
| | |
|
0–9
|
492
|
(3.6)
|
|
10–19
|
368
|
(2.7)
|
|
20–29
|
623
|
(4.6)
|
|
30–39
|
772
|
(5.7)
|
|
40–49
|
885
|
(6.5)
|
|
50–59
|
1650
|
(12)
|
|
60–69
|
2357
|
(17)
|
|
70–79
|
3094
|
(23)
|
|
80–89
|
2859
|
(21)
|
|
≥ 90
|
563
|
(4.1)
|
|
Sex
| | |
|
Women
|
7823
|
(57)
|
|
Men
|
5840
|
(43)
|
|
Any of the comorbidities identified
|
8067
|
(59)
|
|
Charlson Comorbidity Index level
| | |
|
None
|
6058
|
(44)
|
|
Moderate
|
2364
|
(17)
|
|
Severe
|
2374
|
(17)
|
|
Very severe
|
2867
|
(21)
|
|
Comorbidities in the Charlson Comorbidity Index
| | |
|
Myocardial infarction
|
921
|
(6.7)
|
|
Congestive heart failure
|
1050
|
(7.7)
|
|
Peripheral vascular disease
|
803
|
(5.9)
|
|
Cerebrovascular disease
|
1446
|
(11)
|
|
Dementia
|
256
|
(1.9)
|
|
Chronic pulmonary disease
|
1911
|
(14)
|
|
Connective tissue disease
|
983
|
(7.2)
|
|
Ulcer disease
|
848
|
(6.2)
|
|
Mild liver disease
|
171
|
(1.3)
|
|
Diabetes without end-organ damage
|
918
|
(6.7)
|
|
Hemiplegia
|
57
|
(0.42)
|
|
Moderate to severe renal disease
|
643
|
(4.7)
|
|
Diabetes with end-organ damage
|
419
|
(3.1)
|
|
Non-metastatic solid tumor
|
1755
|
(13)
|
|
Leukemia
|
489
|
(3.6)
|
|
Lymphoma
|
834
|
(6.1)
|
|
Moderate to severe liver disease
|
62
|
(0.45)
|
|
Metastatic solid tumor
|
331
|
(2.4)
|
|
Acquired immune deficiency syndrome
|
153
|
(1.1)
|
|
Comorbidities associated with immune dysregulation
|
4942
|
(36)
|
|
Stem cell or bone marrow transplant
|
273
|
(2.0)
|
|
Solid organ transplant
|
152
|
(1.1)
|
|
Human immunodeficiency virus infection
|
210
|
(1.5)
|
|
Primary immunodeficiency
|
61
|
(0.45)
|
|
Any cancer
|
2821
|
(21)
|
|
Any autoimmune disease
|
2293
|
(17)
|
|
Hematologic
|
73
|
(0.53)
|
|
Endocrine
|
614
|
(4.5)
|
|
Central nervous system
|
67
|
(0.49)
|
|
Gastrointestinal
|
274
|
(2.0)
|
|
Skin
|
315
|
(2.3)
|
|
Connective tissue disease
|
1080
|
(7.9)
|
|
Pulmonary
|
31
|
(0.23)
|
|
Ocular
|
94
|
(0.69)
|
